GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Short Percentage of Float

Zelira Therapeutics (ASX:ZLD) Short Percentage of Float


View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Zelira Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Zelira Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelira Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Zelira Therapeutics's Short Percentage of Float falls into.


Zelira Therapeutics (ASX:ZLD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Short Percentage of Float
Comparable Companies
ASX:NSB ASX:IXC ASX:CMB ASX:VBS ASX:ILA ASX:ANR ASX:HXL ASX:AVE ASX:NYR ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ZLDAF:USA G1G:Germany
Address
101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Website
https://www.zeliratx.com
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines